MedPath

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Squamous Cell Carcinoma of Head and Neck
HER2 Negative Breast Neoplasms
Cutaneous Squamous Cell Cancer
Exocrine Pancreatic Adenocarcinoma
Uterine Cervical Neoplasms
Carcinoma, Non-Small Cell Lung
Esophageal Squamous Cell Carcinoma
Urinary Bladder Neoplasms
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Interventions
Registration Number
NCT04389632
Lead Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Brief Summary

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors.

The study will have four parts.

* Part A of the study will find out how much sigvotatug vedotin should be given to participants.

* Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors.

* Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs.

* Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.

* In Parts C and D, participants will receive sigvotatug vedotin with either:

* Pembrolizumab or,

* Pembrolizumab and carboplatin, or

* Pembrolizumab and cisplatin.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1006
Inclusion Criteria
  • Disease indication

    • Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part).

      • Non-small cell lung cancer (NSCLC)
      • Head and neck squamous cell cancer (HNSCC)
      • Advanced HER2-negative breast cancer
      • Esophageal squamous cell carcinoma (ESCC)
      • Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ)
      • Cutaneous squamous cell cancer (cSCC)
      • Exocrine pancreatic adenocarcinoma
      • Bladder cancer
      • Cervical cancer
      • Gastric cancer
      • High grade serous ovarian cancer (HGSOC)
    • Part A only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic options.

    • Part B only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies. Participants must have received platinum-based therapy and a PD-1/PD-(L)1 inhibitor, if applicable and available.

    • Part C only: For pembrolizumab combination cohorts, participants must be eligible for pembrolizumab per local standard of care. For pembrolizumab with cisplatin or carboplatin, participants must be eligible for both pembrolizumab and the platinum agent per local standard of care. Participants must be treatment naïve for locally advanced or metastatic systemic therapy (prior definitively intended or [neo]adjuvant therapy is allowed).

    • Part D only: Participants must be treatment naïve for locally advanced or metastatic systemic therapy.

  • Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows:

    • Disease-specific expansion cohorts (Part B and Part D): A baseline fresh tumor biopsy is required. An archival biopsy collected within 90 days prior to first dose of study drug may be used.
    • Biology expansion cohort: pretreatment biopsy and on-treatment (Cycle 1) biopsy
  • An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

  • Measurable disease per the RECIST v1.1 at baseline

Exclusion Criteria

  • History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.

  • Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:

    • are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,
    • have no new or enlarging brain metastases, and
    • are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug.
    • In Part D, participants with untreated, asymptomatic CNS metastases smaller than 1 cm may be enrolled without definitive treatment as long as they have no neurological symptoms, no or minimal surrounding edema, and no requirements for corticosteroids.
  • Carcinomatous meningitis

  • Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6

  • Pre-existing neuropathy Grade 1 or greater per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) for Parts C and D cohorts with cisplatin or carboplatin; Grade 2 or greater per the NCI CTCAE v5.0 for all other cohorts

  • Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of sigvotatug vedotin.

    • Routine antimicrobial prophylaxis is permitted
  • Grade ≥3 pulmonary disease unrelated to underlying malignancy. This includes clinically severe pulmonary function compromise resulting from clinically significant pulmonary illnesses

  • Part C and D: Prior therapy with a PD-1 inhibitor, anti-PD-(L)1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune-mediated adverse event (IMAE).

  • History of noninfectious interstitial lung disease (ILD) or pneumonitis that required steroids, current ILD or pneumonitis, or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening

  • Known diffusing capacity of the lung for carbon monoxide (DLCO; adjusted for hemoglobin) <50% predicted

  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Part A: Dose escalationsigvotatug vedotinsigvotatug vedotin monotherapy
Part B: Dose expansionsigvotatug vedotinsigvotatug vedotin monotherapy
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCCsigvotatug vedotinsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCCpembrolizumabsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCCcisplatinsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCCcarboplatinsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Part D: sigvotatug vedotin combination therapy in 1L NSCLCsigvotatug vedotinsigvotatug vedotin + pembrolizumab +/- (carboplatin)
Part D: sigvotatug vedotin combination therapy in 1L NSCLCpembrolizumabsigvotatug vedotin + pembrolizumab +/- (carboplatin)
Part D: sigvotatug vedotin combination therapy in 1L NSCLCcarboplatinsigvotatug vedotin + pembrolizumab +/- (carboplatin)
Part D: sigvotatug vedotin combination therapy in 1L HNSCCsigvotatug vedotinsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Part D: sigvotatug vedotin combination therapy in 1L HNSCCpembrolizumabsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Part D: sigvotatug vedotin combination therapy in 1L HNSCCcisplatinsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Part D: sigvotatug vedotin combination therapy in 1L HNSCCcarboplatinsigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
Primary Outcome Measures
NameTimeMethod
Number of participants with dose-limiting toxicities (DLTs)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
Number of participants with adverse events (AEs)Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years

Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Number of patients with laboratory abnormalitiesThrough 30-37 days following last dose of sigvotatug vedotin; up to 3 years
Secondary Outcome Measures
NameTimeMethod
Overall survival (OS)Up to approximately 3 years

The time from the start of any study treatment to the date of death due to any cause

Maximum observed concentration (Cmax)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

PK endpoint

Trough concentration (Ctrough)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

PK endpoint

Number of participants with antidrug antibodies (ADAs)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
Area under the concentration-time curve (AUC)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

Pharmacokinetic (PK) endpoint

Concentration at the end of infusion (Ceoi)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

PK endpoint

Time to maximum observed concentration (Tmax)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

PK endpoint

Duration of objective response (DOR) per RECIST v1.1 by investigator assessmentUp to approximately 3 years

The time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or to death due to any cause

Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator assessmentUp to approximately 3 years

The proportion of participants with complete response (CR) or partial response (PR) which is subsequently confirmed as assessed according to RECIST v1.1.

Progression-free survival (PFS) per RECIST v1.1 by investigator assessmentUp to approximately 3 years

The time from the start of any study treatment to the first documentation of PD, or death due to any cause

Apparent terminal elimination half-life (t1/2)Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

PK endpoint

Trial Locations

Locations (120)

Alaska Oncology and Hematology

🇺🇸

Anchorage, Alaska, United States

Highlands Oncology Group

🇺🇸

Springdale, Arkansas, United States

Providence Medical Foundation

🇺🇸

Fullerton, California, United States

Providence St. Jude Medical Center Virginia K Crosson and Infusion Center

🇺🇸

Fullerton, California, United States

Cancer and Blood Research Center, LLC

🇺🇸

Los Alamitos, California, United States

Cancer and Blood Specialty Clinic

🇺🇸

Los Alamitos, California, United States

Ronald Reagan UCLA Medical Center

🇺🇸

Los Angeles, California, United States

UCLA Department of Medicine-Hematology/Oncology

🇺🇸

Los Angeles, California, United States

UCLA Department of Medicine - Hematology & Oncology

🇺🇸

Santa Monica, California, United States

Cancer AND Blood Specialty Clinic

🇺🇸

Torrance, California, United States

Scroll for more (110 remaining)
Alaska Oncology and Hematology
🇺🇸Anchorage, Alaska, United States
© Copyright 2025. All Rights Reserved by MedPath